Advertisement

Raynaud’s Phenomenon

  • Rüdiger Müller
  • Johannes von Kempis
Chapter
  • 831 Downloads

Diltiazem

Trial

A randomized double-blind trial of Diltiazem in the treatment of Raynaud’s phenomenon

 

Substance

1 Week placebo prior to randomization

Diltiazem 3 × 120 mg/day

Placebo

Cross over after 2 weeks

No information on concomitant medication and precise numbers in each group

 

Result

Diltiazem in the treatment of Raynaud’s phenomenon was effective, especially in patients with idiopathic vasospastic disease

 

Patients

16 patients with Raynaud’s phenomenon

progressive systemic sclerosis n = 7, rheumatoid arthritis n = 2, systemic lupus erythematosus n = 1, idiopathic Raynaud’s phenomenon n = 6

 

Authors

Kahan A, Amor B, Menkes CJ

 

Publication

Ann Rheum Dis. 1985;44(1):30–33

 

Follow up

4 weeks

 

Note

Marked or moderate improvement n = 9 (diltiazem), n = 3 (placebo)

Frequency of attacks/2 weeks:

All patients 18.9 (placebo), 12.6 (diltiazem)

Idiopathic Raynaud’s phenomenon patients 16.3 (placebo), 8.5 (diltiazem)

PSS + RA + SLE patients 20.4 (placebo), 15.1 (diltiazem)

Severity...

Keywords

Public Health Internal Medicine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Springer London 2010

Authors and Affiliations

  • Rüdiger Müller
    • 1
  • Johannes von Kempis
    • 1
  1. 1.Division of Rheumatology and Rehabilitation Department of Internal MedicineKantonsspital St. GallenSt. GallenSwitzerland

Personalised recommendations